We all have to plan for new pricing models in the U.S that could help us ensure sustainability of the system as the U.S. population ages. We are planning for a environment where there are not increases in price in the U.S..

Joe Jimenez

Categorized in : Company News

There's a put( option) in 2018 but as long as there's value that's going to continue to be generated here, we are happy to participate in it.

The UK is an important market for us. There are many countries in Europe, namely Switzerland, which are not in the EU, and we continue to invest in those countries as well as in the EU, we will continue to invest strongly in the UK despite the decision to exit the EU as we see very large areas of unmet medical need and the innovation Novartis brings can help patients in the UK.

I had said it would take about five years to see a product on the market, the calendar is light and we are already developing a technological lens prototype (that) should be tested on humans in 2016.

In the United States, we proposed to insurers a differentiated price calculated according to length of stay, few insurers entered in the field. They told us that the system was too complicated.

This project is progressing well. by Joe Jimenez

This project is progressing well.

There is no project on our side to participate in this consolidation trend because we cannot ensure this growth.

I think there's a conscious effort to slow it down a bit, then on top of that, you have what's happening from an economy standpoint in the stated shift towards what they're calling sustainable economic growth, which is leading to lower overall growth rates.

We'll have to take a hard look at what's in Switzerland and what... by Joe Jimenez

We'll have to take a hard look at what's in Switzerland and what could move outside.

We've done more than most but certainly not enough. You're going to see a continued focus from this company that will be quite technology agnostic, It may be niche today but in the future I think it is going to be front and center as to how diseases are managed.

If there were a wearable device that could help the patient and their physician understand whether or not to come to the hospitals then that, together with our drug, could be a very potent combination, It doesn't mean we will own the technologies, but it does mean the technologies will play an important role in the management of disease.